BAY86-4367 + BAY86-4367
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diagnostic Imaging
Conditions
Diagnostic Imaging
Trial Timeline
Sep 1, 2009 → Oct 1, 2010
NCT ID
NCT00975299About BAY86-4367 + BAY86-4367
BAY86-4367 + BAY86-4367 is a phase 1 stage product being developed by Bayer for Diagnostic Imaging. The current trial status is terminated. This product is registered under clinical trial identifier NCT00975299. Target conditions include Diagnostic Imaging.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00975299 | Phase 1 | Terminated |
Competing Products
11 competing products in Diagnostic Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) | Bayer | Phase 1 | 30 |
| Ultravist (Iopromide, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Gadopentetate dimeglumine (Magnevist, BAY86-4882) | Bayer | Pre-clinical | 20 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Pre-clinical | 20 |
| Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance) | Bayer | Phase 3 | 74 |
| Xenetix + Visipaque | Guerbet | Approved | 77 |
| Iobitridol | Guerbet | Approved | 77 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |